Friday May 9 11:01 AM EDT
Company Press Release
Source: Lidak Pharmaceuticals
LIDAK Pharmaceuticals Reports Additional Data From Kaposps Sarcoma Trial At International Conference
LA JOLLA, Calif., May 9 /PRNewswire/ -- Today at The Second International Conference on Human Herpes Viruses 6, 7, and 8 in Pisa, Italy, LIDAK Pharmaceuticals (Nasdaq:NNM - news) reported additional data from its clinical trials with the topical formulation of its proprietary drug, n-docosanol (LIDAKOL(R)) in the treatment of cutaneous Kaposi's sarcoma.
Previously, the Company reported that topical LIDAKOL exhibited promising efficacy in reducing the progression and severity of Kaposi's sarcoma (KS) skin lesions in HIV-1-infected patients. The preliminary results of the study were presented, in Pisa, by Dr. Michael J. Scolaro, the investigator who conducted the pilot study in Los Angeles.
LIDAK studied the efficacy and safety of n-docosanol 10% cream as a treatment of cutaneous KS lesions in ten HIV-1-infected patients. In the study, twenty-eight KS lesions were evaluated weekly for four weeks for effects of treatment on pigmentation, size and form (i.e. hard, soft, raised, flat, swollen) of the lesions. Topical treatment with n-docosanol 10% cream resulted in a highly significant (p<0.00098) decrease in overall mean lesion size with nearly 20% of lesions diminishing by more than 50%. Nine of the ten patients experienced pronounced lightening of lesion pigmentation within four weeks.
Pertinent additional results presented by Dr. Scolaro at the Second International Conference on Human Herpes Viruses 6, 7, and 8 were as follows:
1) By three months after treatment initiation, all ten patients (100%) manifested a decrease in lesion size;
2) Histological assessments in two of these patients, comparing pre- treatment and post-treatment biopsy specimens, has verified the absence of KS in one instance, and significant regression of the disease in the other.
3) None of the patients developed any apparent signs of systemic spread of the disease, including oral KS lesions which are generally the first sign of systemic dissemination of the disease.
Kaposi's sarcoma is a serious AIDS-related disease for which current therapy is unpredictable and unpleasant. Recent studies have revealed a close association between KS and human herpesvirus (HHV)-8. Since n-docosanol inhibits most herpes viruses, including HHV-6, a close relative of HHV-8, LIDAK reasoned that it was prudent to study the efficacy and safety of n-docosanol 10% as a treatment of cutaneous KS lesions. Therefore, these preliminary results suggest a promising role for n-docosanol 10% cream as a first-line therapy in the treatment of HIV-1-associated cutaneous KS lesions.
LIDAK Pharmaceuticals is developing therapeutic products against virally caused diseases, inflammatory disorders and cancer.
NOTE TO EDITORS: The information contained in this press release should be reviewed in conjunction with the Company's Annual Report on Form 10-K and other publicly available information regarding the Company, copies of which are available from the Company upon request. Such publicly available information sets forth many risks and uncertainties related to the Company's business, including risks and uncertainties related to drug development and clinical trials.
SOURCE: Lidak Pharmaceuticals
-
More news for referenced ticker symbols: LDAKA, NNM, and related industries: medical.
------------------------------------------------------------------------
Help
------------------------------------------------------------------------
Important Disclaimers and Legal Information
Questions or Comments? |
